News for Cellectar Biosciences, Inc. (CLRB)

Mr. Posner will serve as Chairman of the Audit Committee

On July 2, 2025, James Caruso, the CEO of Cellectar Biosciences Inc, purchased 10,000 shares of the company. Following this transaction, the insider now owns a

Cellectar Biosciences (CLRB) raises $6.9 million through a public offering. The offering includes Class A and Class B Units, with warrants exercisable a

Ladenburg Thalmann has taken on the role of manager for Cellectar Biosciences, Inc. (CLRB). This move is part of a strategic initiative aimed at enhancing the c

Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinica

Shares of Cheetah Mobile Inc. CMCM rose sharply in pre-market trading following first-quarter results. Cheetah Mobile posted a quarterly loss of 11 cents per s...

FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. ( CLRB), a late-stage clinical biopharmaceutical company focused on the disc

Cellectar Biosciences (CLRB) announces a 1-for-30 reverse stock split, effective on June 24, 2025. The reverse split will reduce outstanding shares from

Cellectar Biosciences, under the ticker CLRB, has unveiled a reverse stock split on a one-for-thirty basis, set to take effect on Tuesday, June 24. The stock wi

**media[658945]**

**media[651743]**

Cellectar Biosciences (CLRB) has achieved a significant milestone with its lead drug, iopofosine I 131, receiving Breakthrough Therapy Designation from the U.S.

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday. The Dow traded up 0.09% to 42,558....

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Wednesday. Following the market opening Wednesday, the Dow trad...

Transaction Overview On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) made a strategic decision to reduce its holdings in Cellectar B

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming  Biotech Showcase during the JP Morgan Healthcare Conference

Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy Endpoints in Phase 2 CLOVER-Wa

Cellectar Biosci stock hits 52-week low at $0.27 amid sharp decline

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.22%